AMGEN Inc.

NASDAQ:AMGN  
227.57
-1.33 (-0.58%)
4:00:02 PM EDT: $227.72 +0.15 (+0.07%)
Products

FDA Approves Otezla® (Apremilast) For The Treatment Of Adult Patients With Plaque Psoriasis, Regardless Of Severity Level

Published: 12/20/2021 21:41 GMT
AMGEN Inc. (AMGN) - FDA Approves Otezla® (apremilast) for the Treatment of Adult Patients With Plaque Psoriasis, Regardless of Severity Level.
Amgen Inc - FDA Approval is Based on Findings From Phase 3 Advance Trial.